Inspyr Therapeutics, Inc., an early-stage pharmaceutical company, focuses on the discovery and development of prodrug cancer therapeutics in the United States. It develops cancer therapeutics for the treatment of solid tumors, including brain, liver, prostate, and other cancers. The company's lead drug candidate is mipsagargin, which has completed an open label single arm Phase II clinical trial in patients with advanced hepatocellular carcinoma or liver cancer. The company was formerly known as GenSpera Inc. and changed its name to Inspyr Therapeutics, Inc. in August 2016. Inspyr Therapeutics, Inc. was founded in 2003 and is based in Westlake Village, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/12/2019 10:29 PST] Inspyr Therapeutics, Inc. (OTC:NSPX), Up By 100.00% ($0.01) After BUYINS.NET SqueezeTrigger Report Released on Monday, February 11th 2019 at a Price of $0.007.
• [02/11/2019 12:05 PST] Inspyr Therapeutics, Inc. (OTC:NSPX), Up By 100.00% ($0.01) After BUYINS.NET SqueezeTrigger Report Released on Monday, January 28th 2019 at a Price of $0.006.
• [02/11/2019 11:07 PST] NSPX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [01/28/2019 11:45 PST] NSPX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.